<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710788</url>
  </required_header>
  <id_info>
    <org_study_id>2008.1</org_study_id>
    <secondary_id>2008.1.brd.renagel</secondary_id>
    <nct_id>NCT00710788</nct_id>
  </id_info>
  <brief_title>Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis</brief_title>
  <acronym>Independent</acronym>
  <official_title>Interventional, Multicenter, Prospective, Randomized Trial to Slow Down the Progression of Cardiovascular Calcifications to Reduce QTd in Incident Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria ASL Avellino 2</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Sanitaria ASL Avellino 2</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research proposal to evaluate the impact of different phosphate binders on the progression of
      cardiovascular calcification and QT dispersion in new haemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risk of developing cardiovascular diseases in patients on hemodialysis is higher than in
      general population. Higher levels of serum phosphate are associated with adverse
      cardiovascular outcomes, especially in the setting of overt hyperphosphatemia. Given the
      biological importance of serum phosphorus, it is conceivable that also within the normal
      range values the higher serum phosphate levels may be associated with the worst outcome.
      Several paper have shown that vascular calcifications in dialysis patients are associated
      with increased relative risk of death; it has also been demonstrated in uremic patients that
      vascular calcifications decrease arterial elasticity. We previously observed that vascular
      calcification directly correlate with QT interval (QTc) as well as QT dispersion (QTd) in
      dialysis. Also, QT correction (obtained by the correction of phosphoremia and dyslipidemia)
      can ameliorate the development of arrhythmia and sudden death. Aim of this study is to
      evaluate the relationship between vascular calcifications and both QTd increase and mortality
      in incident hemodialysis patients, and to investigate the efficacy of sevelamer to reduce
      vascular calcifications and QTd.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death due to cardiac arrhythmias or as sudden cardiac death defined as any deaths coded as &quot;cardiac arrest, cause unknown&quot; or &quot;cardiac arrhythmia&quot; without any exclusions</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QT interval; PWV; mortality for acute myocardial infarction, cerebral vascular accident and heart failure; Non-CV mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Cardiovascular Mortality</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sevelamer as Phosphate-binder treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium carbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer phosphate-binders</intervention_name>
    <description>1600 mg/day for 2 years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Renagel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Calcium carbonate 1 g/day for 2 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  incident patients on haemodialysis (CKD stage 5);

          -  an informed consent will be provided at the study entry.

        Exclusion Criteria:

          -  congenital prolongation of QT segment syndrome;

          -  QTc &gt;440 ms; increased QTd;

          -  bradycardia &lt;50 bpm;

          -  sintomatic arrhythmia or any other significant heart problems;

          -  electrolyte unbalances (especially hypokalemia, hypomagnesemia, hypocalcemia);

          -  abnormal liver function tests;

          -  hypothyroidism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biagio R Di Iorio, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ASL AV/2, Avellino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loreto Gesualdo, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Division, Medical School, University of Foggia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filippo Aucella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASL FG, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter De Simone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO MOscati, Avellino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Migliorati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysis, Torre del Greco, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domenico Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Division, Medical School, University of Messina, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasquale Guastaferro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Division, ASL AV1, Sant'Angelo de Lomnardi, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Chiuchuilo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysis, Avellino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Tedesco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysis, Montella, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Division</name>
      <address>
        <city>Solofra</city>
        <state>Avellino</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Di Iorio B, D'Avanzo E, Piscopo C, Cucciniello E, Bellizzi V: QT and phosphatemia: a novel sensitive marker of cardiovascolar risk for an old killer . 12th Assisi European Meeting on Cardionephrology, Cardionephrology 10, Nuova BIOS ed, 2008;23-26</citation>
  </reference>
  <results_reference>
    <citation>Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer--are they of clinical relevance? Semin Dial. 2008 Sep-Oct;21(5):385-9. doi: 10.1111/j.1525-139X.2008.00440.x. Epub 2008 Jun 19. Review.</citation>
    <PMID>18573137</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Iorio BR, Bortone S, Piscopo C, Grimaldi P, Cucciniello E, D'Avanzo E, Mondillo F, Cillo N, Bellizzi V. Cardiac vascular calcification and QT interval in ESRD patients: is there a link? Blood Purif. 2006;24(5-6):451-9. Epub 2006 Aug 25.</citation>
    <PMID>16940716</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Iorio BR, D'Avanzo E, Piscopo C, Grimaldi P, Cucciniello E, Cillo N, Bellizzi V. Progression of vascular calcification increases QT interval in haemodialysis patients. Nephrol Dial Transplant. 2006 Dec;21(12):3609-10. Epub 2006 Jul 31.</citation>
    <PMID>16880182</PMID>
  </results_reference>
  <results_reference>
    <citation>Cozzolino M, Galassi A, Pasho S, Fallabrino G, Gallieni M, Brancaccio D. Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contrib Nephrol. 2008;161:234-9. doi: 10.1159/000130696. Review.</citation>
    <PMID>18451682</PMID>
  </results_reference>
  <results_reference>
    <citation>Nolan CR, McCarron DA. Lack of mortality benefit with sevelamer. Kidney Int. 2008 May;73(9):1093; author reply 1093-4. doi: 10.1038/ki.2008.46.</citation>
    <PMID>18414441</PMID>
  </results_reference>
  <results_reference>
    <citation>Wrong O, Harland C. Sevelamer. Nephrol Dial Transplant. 2008 Jun;23(6):2108; author reply 2101-2. doi: 10.1093/ndt/gfn162. Epub 2008 Apr 9.</citation>
    <PMID>18400812</PMID>
  </results_reference>
  <results_reference>
    <citation>Negri AL. [K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment]. Nefrologia. 2007;27(6):670-3. Review. Spanish.</citation>
    <PMID>18336094</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. Saudi J Kidney Dis Transpl. 2008 Mar;19(2):183-8.</citation>
    <PMID>18310864</PMID>
  </results_reference>
  <results_reference>
    <citation>St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008 Mar;51(3):445-54. doi: 10.1053/j.ajkd.2007.12.002.</citation>
    <PMID>18295060</PMID>
  </results_reference>
  <results_reference>
    <citation>Winkelmayer WC, Tonelli M. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice. Am J Kidney Dis. 2008 Mar;51(3):362-5. doi: 10.1053/j.ajkd.2008.01.004.</citation>
    <PMID>18295050</PMID>
  </results_reference>
  <results_reference>
    <citation>Mansour J, Shahapuni I, El Esper N, Fournier A. Block randomized trial evidencing lower mortality with sevelamer compared with calcium phosphate binder in incident dialysis patients. Kidney Int. 2008 Feb;73(4):510. doi: 10.1038/sj.ki.5002752.</citation>
    <PMID>18235525</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreira A, Fraz√£o JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH; Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405-12. doi: 10.1681/ASN.2006101089. Epub 2008 Jan 16.</citation>
    <PMID>18199805</PMID>
  </results_reference>
  <results_reference>
    <citation>Suki WN; Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr. 2008 Jan;18(1):91-8.</citation>
    <PMID>18089452</PMID>
  </results_reference>
  <results_reference>
    <citation>Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007 Nov;72(10):1255-61. Epub 2007 Sep 5.</citation>
    <PMID>17805238</PMID>
  </results_reference>
  <results_reference>
    <citation>Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007 Nov;72(9):1130-7. Epub 2007 Aug 29.</citation>
    <PMID>17728707</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>February 9, 2013</last_update_submitted>
  <last_update_submitted_qc>February 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Sanitaria ASL Avellino 2</investigator_affiliation>
    <investigator_full_name>Dr Biagio Di Iorio</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>QT interval</keyword>
  <keyword>QT dispersion</keyword>
  <keyword>arrhythmias</keyword>
  <keyword>death</keyword>
  <keyword>TC score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

